Smoking and schizophrenia: is symptom profile related to smoking and which antipsychotic medication is of benefit in reducing cigarette use?

References

• de Leon J, Diaz F J. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviours. Schizophrenia Research 2005; 76: 135–157
   PubMed Web of Science ®Google Scholar
• Dalak G W, Becks L, Hill E, Pomerleau O F, Meador-Woodruff J H. Nicotine withdrawal and psychiatric symptoms in cigarette smokers with schizophrenia. Neuropsychopharmacology 1999; 21: 195–202
   PubMedGoogle Scholar
• Hughes J R, Frances R J. How to stop psychiatric patients stop smoking. Psychiatric Services 1995; 46: 435–437
   PubMed Web of Science ®Google Scholar
• Hughes J R, Hatsukami D K, Mitchell J E, Dahlgren L A. Prevalence of smoking among psychiatric outpatients. American Journal of Psychiatry 1986; 143: 993–997
   PubMed Web of Science ®Google Scholar
• Lohr J B, Flynn K. Smoking and schizophrenia. Schizophrenia Research 1992; 8: 93–102
   PubMed Web of Science ®Google Scholar
• Weiser M, Reichenberg A, Grotto I, et al. Higher rates of cigarette smoking in male adolescents before the onset of schizophrenia: a historical-prospective cohort study. American Journal of Psychiatry 2004; 161: 1219–1223
   PubMed Web of Science ®Google Scholar
• Lawrence D M, Holman C D, Jablensky A V, Hobbs M S. Death rate from ischaemic heart disease in Western Australian psychiatric patients. British Journal of Psychiatry 2003; 182: 31–36
   PubMed Web of Science ®Google Scholar
• Davidson M. Risk of cardiovascular disease and sudden death in schizophrenia. Journal of Clinical Psychiatry 2002; 63(Suppl 9)5–11
   PubMedGoogle Scholar
• Le Fevre P D. Improving the physical health of patients with schizophrenia: therapeutic nihilism or realism?. Scottish Medical Journal 2001; 46: 11–23
   PubMedGoogle Scholar
• McCreadie R G. Scottish Co Morbidity Study Group. Use of drugs, alcohol and tobacco by people with schizophrenia: case control study. British Journal of Psychiatry 2002; 181: 321–325
   PubMed Web of Science ®Google Scholar
• Ziedonis D, Williams J M, Smelson D. Serious mental illness and tobacco addiction: a model program to address this common but neglected issue. American Journal of Medical Science 2003; 326: 223–230
   PubMed Web of Science ®Google Scholar
• De Leon J, Tracy J, McCann E, McGrory A, Diaz F J. Schizophrenia and tobacco smoking: a replication study in another US psychiatric hospital. Schizophrenia Research 2002; 56: 55–65
   PubMed Web of Science ®Google Scholar
• Kavanagh D J, McGrath J, Saunders J B, Dore G, Clark D. Substance misuse in patients with schizophrenia: epidemiology and management. Drugs 2002; 62: 743–755
   PubMed Web of Science ®Google Scholar
• Goff D C, Henderson D C, Amico E. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. American Journal of Psychiatry 1992; 149: 1189–1194
   PubMed Web of Science ®Google Scholar
• Silvestri S, Negrete J C, Seeman M B, Shammi C M, Seeman P. Does nicotine affect D2 receptor upregulation? A case-control study. Acta Psychiatrica Scandinavica 2004; 109: 313–317
   PubMedGoogle Scholar
• Scott W K, Zhang F, Stajich J M, Scott B L, Stacy M A, Vance J M. Family-based case-control study of cigarette smoking and Parkinson disease. Neurology 2005; 64: 442–447
   PubMedGoogle Scholar
• Smith R C, Singh A, Infante M, Khandat A, Kloos A. Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology 2002; 27: 479–497
   PubMed Web of Science ®Google Scholar
• Patkar A A, Gopalakrishnan R, Lundy A, Leone F T, Certa K M, Weinstein S P. Relationship between tobacco smoking and positive and negative symptoms in schizophrenia. Journal of Nervous and Mental Diseases 2002; 190: 604–610
   PubMed Web of Science ®Google Scholar
• Adler L E, Hoffer L J, Griffith J, Waldo M C, Freedman R. Normalisation by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biological Psychiatry 1992; 32: 607–616
   PubMed Web of Science ®Google Scholar
• Lyon E R. A review of the effects of nicotine on schizophrenia and antipsychotic medication. Psychiatric Services 1999; 50: 1346–1350
   PubMed Web of Science ®Google Scholar
• Harris J G, Kongs S, Allensworth D, et al. Effects of nicotine on cognitive deficits in schizophrenia. Neuropsychopharmacology 2004; 29: 1378–1385
   PubMed Web of Science ®Google Scholar
• Noordsy D L, Green A I. Pharmacotherapy for schizophrenia and co-occurring substance use disorders. Current Psychiatry Reports 2003; 5: 340–346
   PubMedGoogle Scholar
• McEvoy J P, Freudenreich O, Wilson W H. Smoking and therapeutic response to clozapine in patients with schizophrenia. Biological Psychiatry 1999; 46: 125–129
   PubMed Web of Science ®Google Scholar
• The Royal Australasian College of Physicians (RACP) and The Royal Australian and New Zealand College of Psychiatrists (RANZCP). Using evidence for better outcomes. Tobacco Policy – Draft 2005.
   Google Scholar
• Woods S W. Chlorpromazine equivalent doses for newer atypical antipsychotics. Journal of Clinical Psychiatry 2003; 64: 663–667
   PubMed Web of Science ®Google Scholar
• Misdrahi D, Llorca P M, Lanson C, Bayle F J. Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications. L’Encephale 2002; 28: 266–272
   PubMed Web of Science ®Google Scholar
• Yang Y K, McEvoy J P, Wilson W H, Levin E D, Rose J E. Reliabilities and intercorrelations of reported and objective measures of smoking in patients with schizophrenia. Schizophrenia Research 2003; 60: 9–12
   PubMedGoogle Scholar
• Kay S R. Positive–negative symptoms assessment in schizophrenia: psychometric issues and scale comparison. Psychiatric Quarterly 1990; 61: 163–178
   PubMedGoogle Scholar
• Goldberg D. Detection of a psychiatric illness by questionnaire. Oxford University Press, London 1972
   Google Scholar
• Reitan R M. Validity of the Trail-making Test as an indicator of organic brain damage. Perceptual and Motor Skills 1958; 8: 271–276
   Google Scholar
• Barnes TRE A rating scale for drug-induced akathisia. British Journal of Psychiatry 1989; 154: 672–676
   PubMedGoogle Scholar
• Chouinard G, Ross-Chouinard A, Annable L, Jones B D. The extrapyramidal symptom rating scale. The Canadian Journal of Neurological Sciences 1980; 7: 233
   Web of Science ®Google Scholar
• Brazo P, Delamillieure P, Morello R, Halbecq I, Marie R M, Dollfus S. Impairments of executive/attentional functions in schizophrenia with primary and secondary negative symptoms. Psychiatry Research 2005; 133: 45–55
   PubMed Web of Science ®Google Scholar
• Asarnow R F, MacCrimmon D J. Attention/information processing, neuropsychological functioning and thought disorder during the acute and partial recovery phases of schizophrenia: a longitudinal study. Psychiatry Research 1982; 7: 309–319
   PubMed Web of Science ®Google Scholar
• Smith R C, Infante M, Ali A, Nigam S, Kotsaftis A. Effects of cigarette smoking on psychopathology scores in patients with schizophrenia: an experimental study. Substance Abuse 2001; 22: 175–186
   PubMedGoogle Scholar
• Ryabik B M, Lippmann S B, Mount R. Implementation of a smoking ban on a locked psychiatric unit. General Hospital Psychiatry 1994; 16: 200–204
   PubMedGoogle Scholar
• Anfang M K, Pope H, Jr. Treatment of neuroleptic-induced akathisia with nicotine patches. Psychopharmacology 1997; 134: 153–156
   PubMedGoogle Scholar
• Chiu C C, Lu M L, Huang M C, Chen K P. Heavy smoking, reduced olanzapine levels, and treatment effects: a case report. Therapeutic Drug Monitoring 2004; 26: 579–581
   PubMedGoogle Scholar
• Greenwood-Smith C, Lubman D I, Castle D J. Serum clozapine levels: a review of their clinical utility. Journal of Psychopharmacology 2003; 17: 234–238
   PubMed Web of Science ®Google Scholar
• Spring B, Pingitore R, McChargue D E. Reward value of cigarette smoking for comparably heavy smoking schizophrenic, depressed and non-patient smokers. American Journal of Psychiatry 2003; 160: 316–322
   PubMed Web of Science ®Google Scholar
• Leonard S, Breese C, Adams C, et al. Smoking and Schizophrenia: abnormal nicotinic receptor expression. European Journal of Pharmacology 2000; 393: 237–242
   PubMed Web of Science ®Google Scholar
• Conwell L S, O'Callaghan M J, Andersen M J, Bor W, Najman J M, Williams G M. Early adolescent smoking and a web of personal and social disadvantage. Journal of Paediatrics and Child Health 2003; 39: 580–585
   PubMed Web of Science ®Google Scholar
• Imperato A, Mulas A, Di Chiara G. Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. European Journal of Pharmacology 1986; 132: 337–338
   PubMed Web of Science ®Google Scholar
• Blum K, Braverman E R, Holder J M, et al. Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behavior. Journal of Psychoactive Drugs 2000; 32(Suppl i–iv)1–112
   Google Scholar
• Meltzer H Y. What's atypical about atypical antipsychotic drugs. Current Opinion in Pharmacology 2004; 4: 53–57
   PubMed Web of Science ®Google Scholar
• Ishikane T. Effects of serotonergic drugs on the up-regulation of dopamine D2 receptors induced by haloperidol in rat striatum. Hokkaido Igaku Zasshi 1998; 73: 441–449
   PubMedGoogle Scholar
• Joyce J N. D2 but not D3 receptors are elevated after 9 or 11 months chronic haloperidol treatment: influence of withdrawal period. Synapse 2001; 40: 137–144
   PubMedGoogle Scholar
• Haustein K O, Haffner S, Woodcock B G. A review of the pharmacologicaland psychopharmacological aspects of smoking and smoking cessation in psychiatric patients. International Journal of Clinical Pharmacology and Therapeutics 2002; 40: 404–418
   PubMed Web of Science ®Google Scholar
• Dalack G W, Meador-Woodruff J K. Smoking, smoking withdrawal and schizophrenia: case reports and a review of the literature. Schizophrenia Research 1996; 22: 133–141
   PubMed Web of Science ®Google Scholar
• George T P, Vessicchio J C, Termine A, et al. A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biological Psychiatry 2002; 1: 53–61
   Google Scholar
• Steinberg M L, Ziedonis D M, Krejci J A, Brandon T H. Motivational interviewing with personalised feedback: a brief intervention for motivating smokers with schizophrenia to seek treatment for tobacco dependence. Journal of Consulting and Clinical Psychology 2004; 72: 723–728
   PubMed Web of Science ®Google Scholar
• Kavanagh D J, Young R, White A, et al. A brief motivational intervention for substance misuse in recent onset psychosis. Drug and Alcohol Review 2004; 23: 151–155
   PubMed Web of Science ®Google Scholar